Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

Rhapsody Launches AI for Identity with Rhapsody Autopilot

What You Should Know: – Rhapsody, a leader in digital health enablement, has unveiled a groundbreaking technology called Rhapsody Autopilot. – The first-of-its-kind solution utilizes

March 9, 2024

AI algorithm with high diagnostic accuracy helps improve lung cancer detection

Assistance from an artificial intelligence (AI) algorithm with high diagnostic accuracy improved radiologist performance in detecting lung cancers on chest X-rays and increased human acceptance

June 27, 2023

Beckman Coulter Life Sciences Revolutionizes Nanoparticle Analysis, Enabling Characterization Down To 40 nm With Launch of CytoFLEX nano Flow Cytometer

March 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.